Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19037577 | 0.83 | CYP2A6 (0.58) | GRM5KDM4EGAAMDM2TDP1 | |
| SCHEMBL19037592 | 0.79 | KDM4E (0.57) | KDM4EGAAMDM2TDP1SMN1; SMN2 | |
| SCHEMBL2121006 | 0.79 | CYP2A6 (0.56) | GRM5KDM4ETDP1SMN1; SMN2TP53 | |
| SCHEMBL3660432 | 0.79 | GRM5 (0.48) | GRM5KDM4ETDP1SMN1; SMN2TP53 | |
| SCHEMBL19037593 | 0.75 | CYP2A6 (0.54) | GRM5KDM4EGAAMDM2SMN1; SMN2 | |
| SCHEMBL4179017 | 0.74 | GRM5 (0.71) | GRM5KDM4ESMN1; SMN2TP53PKM | |
| SCHEMBL3663869 | 0.73 | GRM5 (0.36) | GRM5KDM4ETDP1SMN1; SMN2TP53 | |
| SCHEMBL4183866 | 0.73 | CYP2A6 (0.36) | GRM5KDM4ETDP1SMN1; SMN2TP53 | |
| SCHEMBL4197856 | 0.70 | GRM5 (0.61) | GRM5KDM4ESMN1; SMN2TP53PKM | |
| SCHEMBL3667875 | 0.70 | GPR39 (0.37) | GRM5KDM4ETDP1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298337-A1 | Organic Compounds | CYP11B2, TNNT2, CPT1B | GRM5 4496/4885KDM4E 3699/4885GAA 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.